Stress-responsive Entamoeba topoisomerase II: a potential anti-amoebic target

Topoisomerases are ubiquitous enzymes, involved in all DNA processes across the biological world. These enzymes are also targets for various anticancer and antimicrobial agents. The causative organism of amoebiasis, Entamoeba histolytica (Eh), has seven unexplored genes annotated as putative topoisomerases. One of the seven topoisomerases in this parasite was found to be highly up-regulated during heat shock and oxidative stress. The bioinformatic analysis shows that it is a eukaryotic type IIA topoisomerase. Its ortholog was also highly up-regulated during the late hours of encystation in E. invadens (Ei), the encystation model of Eh. Immunoprecipitated endogenous EhTopoII showed topoisomerase II activity in vitro. Immunolocalization studies show that this enzyme colocalized with newly forming nuclei during encystation, which is a significant event in maturing cysts. Double-stranded RNA mediated down-regulation of the TopoII both in Eh and Ei reduced the viability of actively growing trophozoites and also reduced the encystation efficiency in Ei. Drugs, targeting eukaryotic topoisomerase II, e.g., etoposide, ICRF193, and amsacrine, show 3-5 times higher EC50 in Eh than that of mammalian cells. Sequence comparison with human TopoII showed that key amino acid residues involved in the interactions with etoposide and ICRF193 are different in Entamoeba TopoII. Interestingly, ciprofloxacin an inhibitor of prokaryotic DNA gyrase showed about six times less EC50 value in Eh than that of human cells. The parasites notable susceptibility to prokaryotic topoisomerase drugs in comparison to human cells opens up the scope to study this invaluable enzyme in the light of an antiamoebic target.